Skip to main content
Retour
Watch Compare

Immuneering Corp

Qualité des données : 83%
IMRX
NASDAQ Manufacturing Chemicals
5,57 €
▼ 0,18 € (-3,13%)
6 months return
—
Momentum
Neutral
ROE
-43,61%

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-43,61%
Au-dessus de la moyenne du secteur (-54,47%)
ROIC-35,52%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio24,00
Interest CoverageN/A

Valorisation

PE (TTM|NTM)
-6,40 | -4,25
En dessous de la moyenne du secteur (-1,50)
P/B Ratio1,57
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -45,49 M

Price History

Tendances Financières

Objectif de Cours des Analystes

6 analystes
Buy
+205.2%
upside to target
Actuel
5,57 €
Consensus Target
17,00 €
11,00 €
Bas
30,00 €
Haut
Prévisions
P/E Prévisionnel
-4,25
BPA Prévisionnel
-1,35 €
CA Est.
19,20 M

Surprises de Résultats

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -0,25 € · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -0,42 € -0,40 € -0,38 € -0,18 € — —
Estimate -0,59 € -0,40 € -0,39 € -0,31 € -0,25 € -0,28 €
Surprise +28,21% -0,50% +2,15% +42,25% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -43,61% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -56,02 M
ROE -43,61% ROA -39,86%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -45,49 M
ROIC -35,52% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 24,00
Debt / Equity N/A Current Ratio 24,00
Interest Coverage N/A Asset Turnover N/A
Working Capital 219,56 M Tangible Book Value 220,96 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -6,40 · EV/EBITDA: N/A
P/E Ratio -6,40 Forward P/E -4,25
P/B Ratio 1,57 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 18,69 Fwd Earnings Yield N/A
FCF Yield -12,68%
Market Cap 358,82 M Enterprise Value 131,26 M

Per Share

EPS: -1,27 · FCF/Share: -0,70
EPS (Diluted TTM) -1,27 Revenue / Share N/A
FCF / Share -0,70 OCF / Share -0,70
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 81,19% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 81,19%
SBC-Adj. FCF -51,80 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — 0,0 316 952,0 2,08 M
Net Income -56,02 M -61,04 M -53,47 M -50,51 M -33,54 M
EPS (Diluted) -1,27 -2,04 -1,88 -1,90 -2,46
Gross Profit — — 0,0 158 830,0 926 888,0
Operating Income -59,38 M -64,07 M -58,41 M -51,74 M -33,89 M
EBITDA — — — — —
R&D Expenses 42,05 M 47,96 M 41,62 M 36,27 M 26,54 M
SG&A Expenses — — — — —
D&A 324 517,0 355 807,0 — — —
Interest Expense — — — — —
Income Tax 0,0 — — -307 485,0 -307 485,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 231,99 M 52,71 M 102,58 M 122,37 M 166,70 M
Total Liabilities 13,50 M 11,33 M 12,01 M 12,52 M 10,72 M
Shareholders' Equity 218,48 M 41,39 M 90,58 M 109,85 M 155,98 M
Total Debt — — — — —
Cash & Equivalents 128,65 M 36,14 M 59,41 M 72,64 M 74,89 M
Current Assets 176,25 M 39,59 M 89,08 M 108,75 M 152,33 M
Current Liabilities 10,07 M 7,50 M 7,85 M 8,05 M 5,63 M

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -6,4 -1,5
P/B 1,6 1,6
ROE % -43,6 -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,9
D/E — 0,3

ETFs Holding This Stock
CNCR CNCR
1,01% weight
BRUSX BRUSX
0,44% weight
BRSIX BRSIX
0,08% weight